B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Piper Sandler Maintains Overweight on Altimmune, Maintains $25 Price Target
Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position
Buy Rating Justified by Altimmune's Promising Pemvidutide Efficacy in NASH Treatment
Altimmune Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH
Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements
J.P. Morgan Securities: Maintaining the Altimmune (ALT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $24.00.
Altimmune Analyst Ratings
JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
Altimmune Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Altimmune Analyst Ratings
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12
Altimmune's Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Altimmune Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)